Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats

被引:33
作者
Muschamp, JW [1 ]
Siviy, SM [1 ]
机构
[1] Gettysburg Coll, Dept Psychol, Gettysburg, PA 17325 USA
关键词
cannabis; marijuana; addiction; drug abuse; WIN 55,212-2; CB1; receptor; cross-sensitization;
D O I
10.1016/S0091-3057(02)00910-3
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The extent to which acute and repeated administration of the CB1 agonist WIN 55,212-2 would affect the stimulatory properties of amphetamine was assessed in Lewis rats. In the first experiment, Lewis rats were treated with either 1 mg/kg of WIN 55,212-2 or vehicle and subsequently treated with 2 mg/kg amphetamine. Acute treatment with WIN 55,212-2 initially increased locomotor activity and then attenuated the stimulating effect of amphetamine on locomotion and exploration (as measured by rears). In a separate experiment, Lewis rats were given daily injections of either WIN 55,212-2 (1 mg/kg) or vehicle for 10 days and the effects of amphetamine were assessed at 1 and 3 days following the last chronic cannabinoid treatment. Those rats, which had been treated with WIN 55,212-2. had an enhanced response to amphetamine with rearing but not with ambulatory movements, suggesting the occurrence of behavioral cross-sensitization to the ability of amphetamine to increase rearing. These data add to the growing evidence that there is at least some overlap between those neural systems acted upon by cannabinoids and those that are believed to be involved in incentive properties associated with other drugs of abuse. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:835 / 842
页数:8
相关论文
共 57 条
[1]   CANNABINOID PRECIPITATED WITHDRAWAL BY THE SELECTIVE CANNABINOID RECEPTOR ANTAGONIST, SR 141716A [J].
ACETO, MD ;
SCATES, SM ;
LOWE, JA ;
MARTIN, BR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 282 (1-3) :R1-R2
[2]  
Aceto MD, 1996, J PHARMACOL EXP THER, V278, P1290
[3]   Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2 [J].
Aceto, MD ;
Scates, SM ;
Martin, BB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 416 (1-2) :75-81
[4]   The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain [J].
Arnold, JC ;
Topple, AN ;
Mallet, PE ;
Hunt, GE ;
McGregor, IS .
BRAIN RESEARCH, 2001, 921 (1-2) :240-255
[5]   Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine [J].
Arnold, JC ;
Topple, AN ;
Hunt, GE ;
McGregor, IS .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 354 (01) :9-16
[6]   Effects of the cannabinoid CB1 receptor antagonist, SR141716A, after Δ9-tetrahydrocannabinol withdrawal [J].
Beardsley, PM ;
Martin, BR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 387 (01) :47-53
[7]   What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? [J].
Berridge, KC ;
Robinson, TE .
BRAIN RESEARCH REVIEWS, 1998, 28 (03) :309-369
[8]   Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system [J].
Braida, D ;
Pozzi, M ;
Parolaro, D ;
Sala, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 413 (2-3) :227-234
[9]   Conditioned place preference induced by the cannabinoid agonist CP 55,940: Interaction with the opioid system [J].
Braida, D ;
Pozzi, M ;
Cavallini, R ;
Sala, M .
NEUROSCIENCE, 2001, 104 (04) :923-926
[10]   Behavioural sensitization after repeated exposure to Δ9-tetrahydrocannabinol and cross-sensitization with morphine [J].
Cadoni, C ;
Pisanu, A ;
Solinas, M ;
Acquas, E ;
Di Chiara, G .
PSYCHOPHARMACOLOGY, 2001, 158 (03) :259-266